Skip to main content

Deerfield — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

161
Companies
$8.6B
Total invested
$83.8M
Avg. check
27
Industries
Health Care 15Biotechnology 13Therapeutics 8Medical 7Life Science 5Biopharma 5+21 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 161
COTA Healthcare
October 2022

Bringing clarity to cancer. Working to ensure that everyone touched by cancer has a clear path to the right care.

Artificial Intelligence (AI) · New YorkSeries E
ADC Therapeutics
October 2025

ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.

Biopharma · Lausanne$60.0M Post-IPO Equity
Lark
October 2021

Lark is a digital health startup that provides virtual care through AI coaching, smart devices, and tele-monitoring.

Artificial Intelligence (AI) · Mountain View$100.0M Series D
DeepSight Technology
October 2021

DeepSight Technology's vision is to reinvent diagnostic imaging.

Medical Device · San Francisco$25.0M Series A
Atlas Data Storage
March 2026

Atlas Data Storage is an information technology company focused on data storage solutions.

Database · South San FranciscoSeed
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post Ipo Equity
BIOMx
December 2025

BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.

Biotechnology · Ness Ziona$3.0M Post Ipo Equity
Excelsior Sciences
December 2025

Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.

Artificial Intelligence (AI) · New York$70.0M Series A
Nuvalent
November 2025

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.

Biotechnology · Cambridge$500.0M Post Ipo Secondary
Octave
October 2025

Octave is a precision care company that provides diagnostic tools and care solutions for neurodegenerative diseases.

Biotechnology · Menlo ParkGrant
Valneva
October 2025

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.

Biotechnology · Saint-herblain$215.0M Post Ipo Debt
ARS Pharmaceuticals
September 2025

ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.

Biopharma · San Diego$100.0M Post Ipo Debt
Axon Therapies
September 2025

Axon Therapies develops a healthcare device with a neuromodulation approach to treat heart failure.

Health Care · New York$32.0M Series A
Reprieve Cardiovascular
August 2025

Reprieve Cardiovascular is focused on improving outcomes for patients suffering from acute decompensated heart failure.

Health Care · Milford$61.0M Series B
Actio Biosciences
June 2025

Actio Biosciences is a research center that develops drugs for rare diseases.

Bioinformatics · San Diego$66.0M Series B
NeuroFlow
May 2025

NeuroFlow is a HIPAA compliant digital health platform that optimizes the way behavioral healthcare is delivered, tracked, and assessed.

Fitness · Philadelphia$2.8M Grant
Cohere Health
May 2025

Cohere Health is a SaaS company that focuses on improving the efficiency and effectiveness of healthcare delivery.

Consumer Software · Boston$90.0M Series C
Ray Therapeutics
April 2025

Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.

Biotechnology · San Diego$8.0M Grant
Ascertain
April 2025

Ascertain empowers care teams with AI to reduce admin burden and streamline operations for health systems, payers & providers.

Artificial Intelligence (AI) · New York$10.0M Series A
Lomond Therapeutics
March 2025

Lomond Therapeutics creates pharmacological platforms that target escape mutations.

Biopharma · San Diego$20.0M Series Unknown
Perceive Pharma
February 2025

Perceive Pharma operates as a pharmaceutical company.

Life Science · San Francisco$15.0M Series A
GH Research
February 2025

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$150.0M Post Ipo Equity
Ascend Advanced Therapies
November 2024

Ascend helps make and sell gene therapy treatments. We know a lot about how to create and share these special medicines.

Biotechnology · Alachua$130.6M Undisclosed
Cortica
November 2024

Cortica provides neurological therapies for children with autism and other developmental differences.

Health Care · San Diego$80.0M Series Unknown

Where Deerfield invests

Health Care15
Biotechnology13
Therapeutics8
Medical7
Life Science5
Biopharma5

About Deerfield's portfolio

How many companies has Deerfield invested in?

Deerfield has invested in 161 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Deerfield invest in?

Deerfield's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical, Life Science. The firm invests across 27 different industry categories.

What is Deerfield's largest investment?

Among tracked funding rounds, Nuvalent received $500.0M in a Post Ipo Secondary round. Deerfield's total known invested capital is $8.6B.

What is the average investment size for Deerfield?

Deerfield's average investment size is $83.8M across its portfolio of 161 companies.

What are Deerfield's most recent investments?

Recent Deerfield portfolio additions include COTA Healthcare, ADC Therapeutics, Lark, DeepSight Technology, Atlas Data Storage. These companies were founded in 2020 or later.

Reach the founders behind these 161 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →